Guest Column | November 17, 2026

What the Decisions Mean For Participants

By Hedley Rees

healthcare, weight loss treatment, wellness, self-care-GettyImages-2280314804

By the end of the composite example, the supply problem was solved. Stock had been bought from Market B, the QP declaration and comparability documentation were in place, and no site ran out. Three questions were left open: whether participants needed retraining on the new pen, whether they should be told about the change, and whether they should be reconsented.

Each of those is a clinical question. None of them can be answered from the purchase order or the IMPD. They depend on what the change means for people already on treatment, and they need an answer from someone with clinical accountability before the first new pen is dispensed.

What A Change In The Control Arm Means For A Participant

A change of source or presentation reaches a participant in more than one way. Separating these effects helps, because each points to a different decision.

Safety. A new pen puts an unfamiliar device in the hands of someone who has been injecting with a different one for months. Differences in activation steps or hold time are a familiar source of administration errors. For a biologic, comparability data supports the conclusion that the new source behaves like the old one. Someone still has to judge whether that evidence is enough for participants switching mid-treatment, and whether monitoring should be closer for a period afterwards. Safety reports also need to show which version each participant was receiving, otherwise a signal linked to one source will be hard to see.

Consent. Participants agreed to take part on the basis of the information they were given. ICH E6(R3) expects them to be told promptly of new information that may be relevant to their willingness to continue.1 A change in what they inject, or how they inject it, may or may not meet that threshold. Whichever way the decision goes, it should be made and recorded by someone able to explain it to an ethics committee.

The comparison. The control arm is the yardstick for the whole trial. If participants randomized in the first year finish on a different presentation from those randomized later, the medical lead and the statistician need to know, and may want to plan a sensitivity analysis. A change that never reaches the clinical database cannot be accounted for in the results.

Where Sourcing Becomes A Protocol Decision

A sourcing decision becomes a protocol decision when it changes what a participant receives or how they receive it. It also becomes one when it changes what the comparison means. From that point it sits within the sponsor's responsibility for participant safety and the reliability of the results.

ICH E6(R3) asks sponsors to identify the factors critical to the quality of a trial at the design stage and to manage the risks to them proportionately.1 The comparator is plainly one of those factors. Yet, as Part 2 showed, the protocol is usually silent on which sources, versions or substitutions are permitted, and the sourcing strategy is settled somewhere else.

Writing those rules into the protocol or the supply plan changes the character of a mid-study switch. A change within the agreed rules becomes a planned event, with its consequences for participants already worked out. A change outside them tells everyone that clinical review is needed before anything is dispensed.

When The Comparator Runs Short

Comparators are marketed medicines, and marketed medicines go into shortage. They are also reformulated, withdrawn from markets and overtaken as the standard of care. When that happens mid-trial, the questions move quickly from logistics to treatment. Should participants on the comparator arm continue on an alternative source, pause treatment or switch to a different product? Is the trial still testing what it set out to test, and is it still right to randomize new participants to that arm?

During the 2009 oncology shortages, Dr Angeliki Kotsianti built the framework used to make allocation decisions for marketed oncology medicines across nearly two hundred markets. In her experience, the stock position was the easier part. The difficulty was that the clinical standard for those decisions had not been agreed before it was needed. A comparator shortage in a trial is the same problem in a smaller setting, with one added obligation: the people affected agreed to research on the understanding that their care had been planned.

Where Responsibility Should Sit

These decisions belong with a named clinician, usually the medical lead or medical monitor, working alongside clinical supply. Supply leaders often see the risks first. What they usually lack is a route to someone with the authority to decide what a risk means for participants, early enough to shape the sourcing contracts.

Four questions help close that gap. A cross-functional team that includes a clinician accountable for participants should be able to answer them before the comparator is bought.

  1. Which market's product are we buying, and does it match what the protocol, investigators and regulators expect?
  2. If blinding changes the product, what evidence shows it still performs like the marketed medicine, and who has judged that evidence sufficient?
  3. Will any participant move between sources, lots or presentations during treatment? If so, has a clinician agreed that this is acceptable, and what retraining or information will participants need?
  4. If the comparator runs short, is withdrawn or is superseded, who decides what happens to participants on that arm, on what clinical standard, and where is that decision recorded?

Supply leaders do not need to assume clinical authority to put this in place. They can take the sourcing plan to the medical lead before contracts are signed, presenting it  as a set of clinical decisions. They can ask for permitted sources, versions and substitution rules to be written into the protocol or supply plan. And they can agree in advance who decides what happens to participants if the comparator fails, and how that decision will be documented.

In the composite example, those steps would have put the pen change in front of a clinician months before Market B was needed. The questions about training, information and consent would have been answered in advance, and participants randomized in the first year would have known what to expect when their pen changed.

References

  1. International Council for Harmonisation. ICH E6(R3) Guideline for Good Clinical Practice. Adopted January 6, 2025. https://database.ich.org/sites/default/files/ICH_E6%28R3%29_Step4_FinalGuideline_2025
    _0106.pdf

About The Author:

Hedley Rees
Hedley Rees is managing consultant at PharmaFlow Ltd., a specialist consultancy challenging the status quo in pharmaceutical supply and manufacturing.

Hedley partners with pharma and biotech leaders, investors, and policymakers who recognize that today’s fragmented supply chains, outsourcing dependencies, and opaque practices are no longer fit for purpose. Working across nonclinical, clinical, and commercial stages, Hedley helps organizations redesign end‑to‑end supply networks, rethink CDMO strategies, and build operational models that are resilient, data‑driven, and accountable to patients and society.

His work shines a light on hidden risks, perverse incentives, and gaps between regulatory intent and industry behavior. As an outspoken commentator and advocate for change, Hedley contributes to public and boardroom debates on drug shortages, reshoring, vertical integration, and regulatory reform.

He is the author of Transforming the Pharmaceutical Supply Chain (Wiley, 2025) and Supply Chain Management in the Drug Industry: Delivering Patient Value for Pharmaceuticals and Biologics (Wiley, 2011).